Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor. - Concepedia

Concepedia

Publication | Closed Access

Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.

14

Citations

0

References

2020

Year

Daniela Santos‐Faria, José Tavares‐Costa, Mónica Eusébio, Joana Leite Silva, Joana Rodrigues, Joana Sousa‐Neves, Ana Catarina Duarte, Carina Lopes, Ana Valido, Joana Dinis,

Abstract

Our findings showed a significantly higher drug retention for TCZ and RTX, compared with 2nd TNFi, and similar persistence among TCZ and RTX, in patients who discontinued a first-line TNFi. These data corroborate the notion that switching to a biologic with a different mode of action is more effective than to a second TNFi.